Open access · CC-BY
via OpenAlex
Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease
Steven N. Austad, Scott W. Ballinger, Thomas W. Buford, Christy S. Carter, Daniel L. Smith, Victor M. Darley-Usmar, Jianhua Zhang
Acta Pharmaceutica Sinica B · 2021 · ▲ 92 citations
Abstract
Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging and AD are associated with apparent metabolic alterations. As developing effective therapeutic interventions to treat AD is clearly in urgent need, the impact of modulating whole-body and intracellular metabolism in preclinical models and in human patients, on disease pathogenesis, have been explored. There is also an increasing awareness of differential risk and potential targeting strategies related to biological sex, microbiome, and circadian regulation. As a major part of intracellular metabolism, mitochondrial bioenergetics, mitochondrial quality-control mechanisms, and mitochondria-linked inflammatory responses have been considered for AD therapeutic interventions. This review summarizes and highlights these efforts.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.apsb.2021.06.014
- Canonical
- link ↗
- Fetched
- 2026-10-05 MST
Cite this
APA
Austad, S.N., Ballinger, S.W., Buford, T.W., Carter, C.S., Smith, D.L., Darley-Usmar, V.M., & Zhang, J. (2021). Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease. <em>Acta Pharmaceutica Sinica B</em>. https://doi.org/10.1016/j.apsb.2021.06.014
Vancouver
Austad SN, Ballinger SW, Buford TW, Carter CS, Smith DL, Darley-Usmar VM, et al. Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease. Acta Pharmaceutica Sinica B. 2021. doi:10.1016/j.apsb.2021.06.014.
BibTeX
@article{steven2021Target,
title = {Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease},
author = {Steven N. Austad and Scott W. Ballinger and Thomas W. Buford and Christy S. Carter and Daniel L. Smith and Victor M. Darley-Usmar and Jianhua Zhang},
journal = {Acta Pharmaceutica Sinica B},
year = {2021},
doi = {10.1016/j.apsb.2021.06.014},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Neuropeptides 2018
Citation only
Sirtuin 1 and Alzheimer's disease: An up-to-date review
Frontiers in Medicine 2018
Open access · CC-BY
Idiopathic Pulmonary Fibrosis: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics
medRxiv 2023
Preprint · CC-BY
Evaluating the life-extending potential and safety profile of rapamycin: a Mendelian Randomization study of the mTOR pathway
Current Neuropharmacology 2024
Preprint · CC-BY
Drug Target to Alleviate Mitochondrial Dysfunctions in Alzheimer’s Disease: Recent Advances and Therapeutic Implications
International review of neurobiology 2026
Citation only
Therapeutic targeting of brain bioenergetics in Alzheimer’s disease addressing insulin resistance, glucose hypometabolism, and mitochondrial dysfunction
Aging and Disease 2022
Open access · CC-BY